Suven Life Sciences Limited has informed the Exchange regarding Investor Presentation
SUVEN Life Sciences Ltd
Communication to investors September 2019
14-Nov-19
2019-20 Q2 results
Risk statement
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.
14-Nov-19
2019-20 Q2 results
FINANCIAL QUICK VIEW
Q2-FY20 vs Q2-FY19
FY 20 YoY (6 months)
Growth in revenue
191.23%
62.86%
Growth in PAT
302.91%
128.21%
Growth in EBIDTA
274.57%
114.83%
Growth in Pre-R&D EBIDTA
201.43%
88.43%
Increase in R&D Costs
R&D to sales
18.38%
6.49%
-2.15%
5.76%
14-Nov-19
2019-20 Q2 results
MAJOR PROFITABILITY RATIOS
Q2 Sep 19
FY20 – Half Year
PAT to Income
25.83%
26.86%
EBIDTA to Income
Cash Flow to Income
Pre-R&D EBITDA to Income
41.49%
43.40%
27.82%
29.17%
46.73%
49.17%
14-Nov-19
2019-20 Q2 results
Q2 to Q1 COMPARISON
3,100.00
2,100.00
1,100.00
100.00
1,250.00
1,050.00
850.00
650.00
450.00
250.00
50.00
Revenue - INR Million
2,799.00
2,019.93
PAT - INR Million
722.85
571.43
800.00
600.00
400.00
200.00
-
Q1 Jun 19
Q2 Sep 19
Q1 Jun 19
Q2 Sep 19
EBIDTA - INR Million
Pre-R&D EBIDTA - INR Million
1,161.20
930.39
1,061.41
1,307.84
1,580.00
1,080.00
580.00
80.00
Q1 Jun 19
Q2 Sep 19
Q1 Jun 19
Q2 Sep 19
14-Nov-19
2019-20 Q2 results
REVENUE COMPARISON
INR Million
4,818.93
2,799.00
2,958.98
6,000.00
5,000.00
4,000.00
3,000.00
2,000.00
1,000.00
-
961.08
Q2 Sep 18
Q2 Sep 19
HY Sep 18
HY Sep 19
14-Nov-19
2019-20 Q2 results
PAT COMPARISON
INR Million
1,294.28
722.85
567.13
179.41
Q2 Sep 18
Q2 Sep 19
HY Sep 18
HY Sep 19
1,400.00
1,200.00
1,000.00
800.00
600.00
400.00
200.00
-
14-Nov-19
2019-20 Q2 results
EBIDTA COMPARISON
2,500.00
2,000.00
1,500.00
1,000.00
500.00
-
INR Million
2,091.59
1,161.20
973.60
310.01
Q2 Sep 18
Q2 Sep 19
HY Sep 18
HY Sep 19
14-Nov-19
2019-20 Q2 results
R & D – EXPENDITURE
INR Million
283.76
277.66
123.87
146.64
300.00
250.00
200.00
150.00
100.00
50.00
-
Q2 Sep 18
Q2 Sep 19
HY Sep 18
HY Sep 19
14-Nov-19
2019-20 Q2 results
PRE-R&D EBIDTA
INR Million
2,369.25
1,307.84
1,257.36
2,500.00
2,000.00
1,500.00
1,000.00
500.00
433.88
-
14-Nov-19
Q2 Sep 18
Q2 Sep 19
HY Sep 18
HY Sep 19
2019-20 Q2 results
PRE-R&D CASHFLOW
INR Million
1,683.35
925.40
961.58
1,800.00
1,600.00
1,400.00
1,200.00
1,000.00
800.00
600.00
400.00
200.00
-
358.88
Q2 Sep 18
Q2 Sep 19
HY Sep 18
HY Sep 19
14-Nov-19
2019-20 Q2 results
FINANCIAL SNAPSHOT
All figures are in INR Million, other than ratios and EPS
2019-20 Q2
2019-20 Q1
Growth %
2018-19 Q2
Growth %
2019-20 HY
2018-19 HY
Growth %
2,799.00 2,019.93 38.57% 1,307.84 1,061.41 23.22%
961.08 191.23% 4,818.93 433.88 201.43% 2,369.25
2,958.98 1,257.36
62.86% 88.43%
46.73% 1,161.20 41.49% 1,104.95 39.48% 18.54 363.56 722.85 25.83%
52.55% 930.39 24.81% 46.06% 874.55 26.34% 43.30% 13.08 290.04 571.43 26.50% 28.29%
45.15% 49.17% 310.01 274.57% 2,091.59 43.40% 32.26% 253.71 335.51% 1,979.49 41.08% 26.40% 31.62 5.91 653.60 68.40 179.41 302.91% 1,294.28 26.86% 18.67%
42.49% 973.60 114.83% 32.90% 861.53 129.77% 29.12% 16.59 277.81 567.13 128.21% 19.17%
5.68
4.49
1.41
10.17
4.47
127.28 55.91 146.64
127.28 55.50
131.01 11.93%
127.28 55.61
111.41 123.87 18.38% 277.66
127.28
127.28 110.69 283.76
-2.15%
Income Pre-R&D EBITDA
Pre-R&D EBITDA Margin EBITDA EBITDA Margin EBIT EBIT Margin Financing costs Taxes Net Profit after tax NP Margin
EPS (basic & diluted not annualised)
Paid up share capital (One Rupee Share) Depreciation R&D expenses
14-Nov-19
2019-20 Q2 results
News Release
• During the period Suven secures 13 product patents covering
Australia, Canada, Europe, Eurasia, India, Japan, South Korea, South Africa, Sri Lanka and USA
• Updates on CRAMS projects: Total – 117; Phase 1 – 78, Phase 2 –
34, Phase 3 – 1 and commercial – 4.
• Enrolled first patient in Phase 2 study for SUVN-G3031, conducted in USA for the treatment of Narcolepsy associated with or without Cataplexy.
• Suven completed Phase 2A, POC study for SUVN-502, conducted in USA indicated for moderate Alzheimer’s. Since the data lock has occurred, the out-come of the study is expected within 3 weeks and scheduled to present during CTAD 2019 - Alzheimer Congress at San Diego, USA held on December 4-7, 2019.
14-Nov-19
2019-20 Q2 results